Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (Weighted Average) (2018 - 2025)

Historic Shares Outstanding (Weighted Average) for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q1 2025 value amounting to $39.6 million.

  • Whitehawk Therapeutics' Shares Outstanding (Weighted Average) rose 4692.29% to $39.6 million in Q1 2025 from the same period last year, while for Mar 2025 it was $39.6 million, marking a year-over-year increase of 4692.29%. This contributed to the annual value of $27.0 million for FY2024, which is 41.6% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $39.6 million for Q1 2025, which was up 4692.29% from $27.0 million recorded in Q4 2024.
  • Over the past 5 years, Whitehawk Therapeutics' Shares Outstanding (Weighted Average) peaked at $39.6 million during Q1 2025, and registered a low of $2.5 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $21.4 million, with a median of $26.9 million in 2023.
  • In the last 5 years, Whitehawk Therapeutics' Shares Outstanding (Weighted Average) plummeted by 9373.62% in 2021 and then surged by 72484.29% in 2022.
  • Quarter analysis of 5 years shows Whitehawk Therapeutics' Shares Outstanding (Weighted Average) stood at $8.9 million in 2021, then soared by 152.27% to $22.5 million in 2022, then grew by 19.58% to $26.9 million in 2023, then rose by 0.42% to $27.0 million in 2024, then skyrocketed by 46.66% to $39.6 million in 2025.
  • Its last three reported values are $39.6 million in Q1 2025, $27.0 million for Q4 2024, and $27.0 million during Q3 2024.